Care & Cure
Based on ARS Original Technology Company
CureBio
is a Biopharmaceutical Company developing
new peptide drug of cancer and dermatology

Based on ARS original technology platform to develop new drug in Asia’s first company
- New technology from ARS-derived peptides
- Diseases including cancer and new drug development
- Pipeline is a first-in-class drug
- Concept is similar immunotherapeutic drugs
Our vision is the guardian of life and
mission is
Care & Cure

Core technology :
ARS are therapeutic targets
“The emerging biology and therapeutic applications of human ARSs in diseases including autoimmune and rare diseases, and cancer”
Nature reviews drug discovery 18 : 629-650 (2019)

ARSs :
disease associations
Under stress condition,
ARSs are linked to many diseases
: Focused on GRS and AIMP1
PNAS 32 : 11043-11049 (2008)

Publications
Reviews |
Biocon’s target factory Nature Biotechnology. Volume 36 Number 9. September 2018. |
Extracellular activities of aminoacyl-tRNA synthetase: new mediators for cell-cell communication. Top Curr Chem. 344:145-166. |
Aminoacyl-tRNA synthetases and tumorigenesis: more than housekeeping. Nat Rev Cancer. 2011. 11:708-18. |
A tipping point for mistranslation and disease. Nat Struct Mol Bio. 2009. 15:348-9. |
Aminoacyl-tRNA synthetase and their connections to disease. Proc Natl Acad Sci USA. 2008. 105:11043-9. |
Associated Disease Research |
Secreted tryptophanyl-tRNA synthetase as a primary defense system against infection. Nat Microbiol. 2016. 2:16191. |
ARS-interacting multi-functional protein induces proliferation of human bone marrow-derived mesenchymal stem cells by accumulation of b-catenin via fibroblast growth factor receptor 2-mediated activation of Akt. Stem Cells Dev. 2013. 22:2630-40. |
Secreted human glycyl-tRNA synthetase implicated in defense against ERK-activated tumorigenesis. Proc Natl Acad Sci USA. 2012. 109:E640-7. |
Patents
0
International
0
Domestic
Registered Patent |
Composition for preventing and treating inflammatory diseases comprising inhibitor of AIMP2-DX2 as an active ingredient. 10-1067816 |
Functional sitting mat using brain wave. 20-0463994 |
Remote control device for electronic devices using brain wave and image device. 10-1077661 |
NOVEL PEPTIDE AND USE THEREOF. 10-1020658 |
NOVEL PEPTIDE AND USE THEREOF. 5002603 |
Novel peptide and uses thereof. CN101370821 |
Novel fragments of the AIMP1 protein and composition for promoting hair growth comprising thereof. 10-2017796 |
Novel fragments of the AIMP1 protein and composition for promoting hair growth comprising thereof. 10-2024055 |
Topical Pharmaceutical Composition and cosmetic composition comprising the extract of complex herb an active ingredient for preventing and alleviating allergic or non-allergic skin disease. 10-1189938 |
Pharmaceutical Composition and heath care food comprising the extract of complex herb an active ingredient for preventing and treating allergic or non-allergic skin disease. 10-1231446 |
Patent Application |
NOVEL AIMP1 PROTEIN FRAGMENT AND HAIR GROWTH-PROMOTING COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT. 16/320,404 |
NOVEL AIMP1 PROTEIN FRAGMENT AND HAIR GROWTH-PROMOTING COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT. 2019-527105 |
NOVEL AIMP1 PROTEIN FRAGMENT AND HAIR GROWTH-PROMOTING COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT. 17 834780.3 |
NOVEL AIMP1 PROTEIN FRAGMENT AND HAIR GROWTH-PROMOTING COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT. 201780058118.1 |
Fragmented GRS polypeptide, mutants thereof and use thereof. 10-2018-0058647 |
R&D Pipeline
Currently CureBio has three defined development projects, all based on our research on human proteins. Our two drug candidates, NeoPep GT and NeoPep A1H are small peptides. Glycyl-tRNA synthetase (GRS)-derived peptides (NeoPep GT) are a series of anti-tumorigenic peptides derived from the natural immune-surveillance agent, GRS. ARS-interacting multifunctional protein 1 (AIMP1)-derived peptides (NeoPep A1H) comprise a hair growth peptide derived from the natural anti-aging agent, AIMP1. The profile of each drug candidate is described in short in the following diagram.


NeoPep GT
- Drug Candidate : GRS-derived peptide
- Indication : Renal Cell Carcinoma
- Development state : 2020 1q Pre-clinical

NeoPep A1H
- Drug Candidate : AIMP1-derived peptide
- Indication : Dermatology/ Alopecia
- Development state : 2019 4Q Pre-clinical

NeoPep GT
- Drug Candidate : GRS-derived peptide
- Indication : Ovarian Cancer
- Development state : 2019 Optimization of lead
CURE BIO Co., Ltd.
Marketing Headquarters
- Hangang City Life, 834 Olympic-ro, Gangdong-gu, Seoul, 05238 Korea
- T. +82-2-427-3669
- F. +82-2-6280-0257
- E. curebio@curebio.co.kr
Research Headquarters
- 9fl, B-dong, 145 Gwanggyo-ro, Yeongtong-gu, Suwon-si, Gyeonggi-do, 16229 Korea
- T. +82-31-888-9933
- F. +82-31-888-9954
- E. cure-bio@curebio.co.kr